Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Spain

Research and Innovation Action · Running

ENABLE Early Neutralizing Antibodies in Infants Living with Hiv to Enhance Their Life

Coordinator
Servicio Madrileno De Salud, Spain
Runs
1 January 2026 to 31 December 2029
Status
Running
EU funding
€6.2m
Total cost
€6.2m
Partners
21 organisations in 9 countries
Type
Research and Innovation Action
Grant agreement
101190620

What the project is doing

In the project's own words, from its summary on CORDIS.

Early ARV treatment in sub-Saharan Africa (SSA) reaches only approximately 50% of infants born with HIV. Mortality in infants in the first 12 months after diagnosis is still over 10% in early treated infants diagnosed at birth, 25% in infants diagnosed with opportunistic infections. According to our experience, the probability of virological control 1 year after diagnosis is only 25 to 35%, even after the rollout of dolutegravir (DTG).

As a solution for this problem, we propose the addition of four shots of subcutaneous (SC), long-half-life broadly neutralizing antibodies (bNAbs) at diagnosis, and 3, 6 and 9 months after diagnosis, as an add-on to standard oral ART will provide immediate therapeutic benefit and decrease HIV viral load levels in the most critical period of life of children with HIV, allowing for a decreased risk of co-infections, HIV-encephalopathy and death.

We will evaluate for the first time the efficacy of combining two bNAbs (ePGT121v1-LS and VRC07-523-LS, as intensification therapy for ART, to achieve viral suppression within one year after diagnosis in high risk-infants with HIV. The specific aims to achieve this general aim will be: to perform a phase II/III trial with bNAbs, capacity strengthening related with bNAbs in Africa, to characterize biomarkers for anticipating response to bNAbs, to identify the barriers and facilitators of rollout of bNAbs as a treatment, and to liaise with relevant stakeholdersThe pathway to achieve this aim will be a collaborative framework between a scientific network with partners in several SSA countries, producers of bNAbs, and European and African laboratories.

With this approach, the probability of viral suppression 1 year after diagnosis will be increased from 30% to 95% to achieve 2030 UNAIDS 3rd target. This achievement will impact in a reduction of HIV- associated morbidity and mortality in the first year of life and beyond in more than 130 000 infants every year.

Topics

Who is involved

OrganisationCityCountryRole
Servicio Madrileno De SaludMadridSpainCoordinator
Centre Pasteur CameroonYaoundeCMParticipant
Fundacion Para La Investigacion Biomedica Del Hospital Universitario 12 De OctubreMadridSpainThird party
Fundacion Para La Investigacion E Innovacion Biomedica Del Hu Infanta Sofia Y Del HenaresMadridSpainThird party
Fundacion Privada Instituto De Salud Global BarcelonaBarcelonaSpainParticipant
Institut National De La Sante Et De La Recherche MedicaleParisFranceParticipant
Fondazione Penta EtsPadovaItalyParticipant
Universita Degli Studi Di Roma Tor VergataRomaItalyParticipant
Iavi Africa LimitedNairobiKenyaParticipant
Fundacao Ariel Glaser Contra O Sida PediatricoMaputoMZParticipant
Fundacao ManhicaVila Da Manhica MaputoMZParticipant
Universidade Eduardo MondlaneMaputoMZParticipant
Stichting International Aids Vaccine Initiative the NetherlandsAmsterdamNetherlandsThird party
Stichting Radboud Universitair Medisch CentrumNijmegenNetherlandsParticipant
International Aids Vaccine Initiative IncNew YorkUnited StatesAssociatedpartner
The Regents of the University of CaliforniaOaklandUnited StatesAssociatedpartner
Africa Health Research Institute (ahri)DurbanSouth AfricaParticipant
Enhancing Care Foundation NpcDurbanSouth AfricaParticipant
Stellenbosch UniversityStellenboschSouth AfricaParticipant
Umkhuseli Innovation and Research Management NPCPietermaritzburgSouth AfricaParticipant
Wits Health Consortium (pty) LtdJohannesburgSouth AfricaParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI